| 000 | 01748 a2200553 4500 | ||
|---|---|---|---|
| 005 | 20250513220247.0 | ||
| 264 | 0 | _c20000919 | |
| 008 | 200009s 0 0 eng d | ||
| 022 | _a0008-543X | ||
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aHäckel, C G | |
| 245 | 0 | 0 |
_aOverexpression of cathepsin B and urokinase plasminogen activator is associated with increased risk of recurrence and metastasis in patients with chondrosarcoma. _h[electronic resource] |
| 260 |
_bCancer _cSep 2000 |
||
| 300 |
_a995-1003 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S. | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 |
_aBiomarkers, Tumor _xbiosynthesis |
| 650 | 0 | 4 |
_aBone Neoplasms _xdiagnosis |
| 650 | 0 | 4 |
_aCathepsin B _xbiosynthesis |
| 650 | 0 | 4 | _aCathepsin L |
| 650 | 0 | 4 |
_aCathepsins _xmetabolism |
| 650 | 0 | 4 |
_aChondrosarcoma _xdiagnosis |
| 650 | 0 | 4 | _aCohort Studies |
| 650 | 0 | 4 | _aCysteine Endopeptidases |
| 650 | 0 | 4 | _aEndopeptidases |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aFollow-Up Studies |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aImmunohistochemistry |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aMatrix Metalloproteinase 1 _xmetabolism |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aNeoplasm Staging |
| 650 | 0 | 4 | _aPrognosis |
| 650 | 0 | 4 | _aRecurrence |
| 650 | 0 | 4 | _aRisk Factors |
| 650 | 0 | 4 | _aSurvival Analysis |
| 650 | 0 | 4 |
_aUrokinase-Type Plasminogen Activator _xbiosynthesis |
| 700 | 1 | _aKrueger, S | |
| 700 | 1 | _aGrote, H J | |
| 700 | 1 | _aOshiro, Y | |
| 700 | 1 | _aHodges, S | |
| 700 | 1 | _aJohnston, D A | |
| 700 | 1 | _aJohnson, M E | |
| 700 | 1 | _aRoessner, A | |
| 700 | 1 | _aAyala, A G | |
| 700 | 1 | _aCzerniak, B | |
| 773 | 0 |
_tCancer _gvol. 89 _gno. 5 _gp. 995-1003 |
|
| 999 |
_c10911823 _d10911823 |
||